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Linear IgA bullous dermatosis (LABD) is a rare, blistering autoimmune disease 
characterized by linear deposits of IgA at the basement membrane zone (BMZ), with 
possible presence of circulating IgA anti-BMZ antibodies. LABD of childhood is 
usually self-healing, while in adults it follows a more prolonged course and refractory 
cases may rarely occur. The first-line treatment for LABD is dapsone in monotherapy 
or in combination with systemic corticosteroids, but various therapeutic approaches 
have been used in non-responder patients. We report two adult patients with 
refractory LABD successfully treated with enteric-coated mycophenolate sodium (EC-
MPS), a recently introduced formulation of mycophenolic acid (MPA). MPA is an 
immunosuppressive agent that acts inhibiting monophosphate dehydrogenase, a key 
enzyme in the novo synthesis of purines. Based on the present cases, we indicate 
EC-MPS as being a safe and effective adjuvant therapy in the treatment of LABD 
when dapsone or the other steroid-sparing drugs fail. It seems to offer an improved 
gastric side effect profile in comparison with the classic formulation of MPA, namely 
its ester mycophenolate mofetil (MMF).  
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